Read the following passage carefully:
Under the 2026 National Genomic Data Sovereignty Framework, all domestic clinical research entities sequencing human genetic material must store raw genomic reads exclusively on accredited sovereign cloud servers located within national borders. Transfer of anonymized aggregate data across international borders is permitted only if the receiving entity obtains certification from the National Bioethics Council and executes a bilateral data-sharing agreement approved by the Ministry of Health. However, foreign academic institutions engaging in collaborative, non-profit biomedical research are exempt from obtaining Ministry of Health approval, provided their processing protocols adhere strictly to equivalent bioethics standards established under international treaties. Crucially, this regulatory exemption does not apply to any joint initiative involving commercial pharmaceutical enterprises, regardless of whether the primary focus of the specific sub-project is non-profit discovery. State regulatory audits conducted in 2025 revealed that over forty percent of compliance breaches occurred when non-profit academic laboratories shared preliminary genetic sequence files with overseas commercial technology vendors under the mistaken assumption that non-profit sponsorship granted total immunity from regulatory oversight.
Based strictly on the information provided in the passage, which of the following statements must logically be true regarding international transfers of genomic data?
- Foreign non-profit academic institutions engaged in collaborative non-commercial research may receive anonymized aggregate genomic data without Ministry of Health approval if they comply with equivalent treaty-based bioethics standards.Answer
- BDomestic clinical research entities are permitted to transfer raw genomic reads across international borders once the National Bioethics Council certifies the receiving foreign server.
- CA non-profit academic institution involved in a joint venture with a commercial pharmaceutical enterprise can bypass Ministry of Health approval if the specific sub-project is non-profit.
- DOverseas commercial technology vendors are automatically granted regulatory immunity from data-sharing restrictions if their research yields significant global health benefits.